loading page

Astragaloside IV inhibits inflammation caused by influenza virus via ROS/NLRP3/Caspase-1 signaling pathway
  • +5
  • Xiaoli Huang,
  • Yifan Zhou,
  • Yi Li,
  • Ting Wang,
  • Yandong Chen,
  • Yuanhong Zhou,
  • Xiaolin Zhou,
  • Qiang LIU
Xiaoli Huang
Sanxia University First Clinical Hospital
Author Profile
Yifan Zhou
Sanxia University First Clinical Hospital
Author Profile
Yi Li
Sanxia University First Clinical Hospital
Author Profile
Ting Wang
Sanxia University First Clinical Hospital
Author Profile
Yandong Chen
Sanxia University First Clinical Hospital
Author Profile
Yuanhong Zhou
Sanxia University First Clinical Hospital
Author Profile
Xiaolin Zhou
Sanxia University First Clinical Hospital
Author Profile
Qiang LIU
Sanxia University First Clinical Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Astragaloside IV (AS-IV) is the most active monomer in the traditional Chinese herbal medicine Radix Astragali, which has a wide range of antiviral, anti-inflammatory, and anti-fibrosis pharmacological effects, and shows protective effect in acute lung injury. This study utilized the immunofluorescence, flow cytometry, ELISA, RT-qPCR, Western blot and Hematoxylin and eosin(H&E) staining methods to investigate the mechanism of AS-IV in reducing viral pneumonia caused by influenza A virus (IAV) in A549 cells and BALB/c mice. The results showed that AS-IV suppressed ROS production in influenza virus-infected A549 cells in a dose-dependent manner, and subsequently inhibited the activation of NLRP3 inflammasome and Caspase-1, decreased IL-1β and IL-18 secretion. In BALB/c mice infected with Poly (I: C), oral administration of AS-IV can significantly reduce Poly (I: C)-induced acute pneumonia and lung pathological injury. Which provides a new therapeutic strategy for influenza virus infection.
Submitted to Immunity, Inflammation and Disease
29 Jan 2024Reviewer(s) Assigned
18 Mar 2024Review(s) Completed, Editorial Evaluation Pending
19 Mar 2024Editorial Decision: Revise Major
17 Apr 20241st Revision Received
23 Apr 2024Reviewer(s) Assigned